Aptinyx starts Phase II trial of NYX-2925 to treat neuropathic pain

Aptinyx Inc. (Evanston, Ill.) began a Phase II trial of NYX-2925 to treat neuropathic pain associated with diabetic peripheral neuropathy. The double-blind, placebo-controlled, U.S. trial will evaluate multiple dose levels of once-daily NYX-2925 for 4 weeks in about 300 patients.

The trial’s primary endpoint is average pain intensity per a numeric rating scale (NRS). Secondary endpoints include daily worst pain intensity and average pain upon walking per an NRS, Brief Pain Inventory for Diabetic Peripheral Neuropathy (BPI-DN) and Patient Global Impression of Change (PGI-C)...